Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals Completes Convertible Notes Offering
Summary
Alnylam Pharmaceuticals, Inc. has completed its offering of $661.25 million in aggregate principal amount of 0.00% Convertible Senior Notes due 2028, including an additional $86.25 million exercised by initial purchasers. The company also entered into capped call transactions to mitigate dilution and repurchased $637.8 million of existing notes. The notes offering, capped call transactions, and note repurchase are detailed in the filing, with relevant exhibits provided.
Profitelligence Alerts
Get alerts for ALNY
Be first to know when Alnylam Pharmaceuticals Inc. files with the SEC.
Filing Categories
Advertisement
About Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals Inc. is a pioneering biotechnology company dedicated to transforming the lives of patients through RNA interference (RNAi) therapeutics. This scientific approach allows for innovative treatments that can silence genes responsible for certain diseases, offering a unique angle on genetic therapies. Alnylam's primary focus is on developing therapeutics for genetic, cardio-metabolic, hepatic infectious, and central nervous system diseases, contributing to redefining how these conditions are treated. The company's groundbreaking work in RNAi provides a platform for addressing otherwise untreatable or poorly managed medical conditions, positioning it as a leader in the biotechnology sector. With numerous collaborations, partnerships, and a growing pipeline of therapeutics, Alnylam plays a crucial role in advancing modern medicine and contributing to the evolving landscape of genetic therapeutics. Headquartered in Cambridge, Massachusetts, Alnylam underscores the critical intersection of innovation, medicine, and gene science in the financial and pharmaceutical markets.
Official SEC Documents
Advertisement